All Pharma News
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GLOBENEWSWIRE
04 Jan 2024
Share Share
Dr. Alan Kivitz to Chair XBiotech™s Natrunix Program in Rheumatoid Arthritis

Dr. Alan Kivitz to Chair XBiotech™s Natrunix Program in Rheumatoid Arthritis
GLOBENEWSWIRE
14 Nov 2023
Share Share
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin
GLOBENEWSWIRE
26 Sep 2023
Share Share
XBiotech Announces Enrollment Completion of Ph II, Placebo Controlled

XBiotech Announces Enrollment Completion of Ph II, Placebo Controlled
GLOBENEWSWIRE
30 Aug 2023
Share Share
XBiotech Announces First Patient Begins Novel Natrunix Therapy in PII RA Trial

XBiotech Announces First Patient Begins Novel Natrunix Therapy in PII RA Trial
GLOBENEWSWIRE
08 Aug 2023
Share Share
XBiotech Commences Tender Offer to Purchase $80,000,000 Worth of Its Shares

XBiotech Commences Tender Offer to Purchase $80,000,000 Worth of Its Shares
GLOBENEWSWIRE
17 May 2023
Share Share
XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™

XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™
GLOBENEWSWIRE
13 Oct 2022
Share Share
XBiotech Successfully Completes PI portion of Pancreatic Cancer Study

XBiotech Successfully Completes PI portion of Pancreatic Cancer Study
GLOBENEWSWIRE
20 Jun 2022
Share Share
XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix

XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix
GLOBENEWSWIRE
28 Apr 2022
Share Share
Why Are XBiotech Shares Trading Higher Today

Why Are XBiotech Shares Trading Higher Today
Vandana Singh BENZINGA
28 Apr 2022
Share Share